IL2 and metastatic melanoma: High-dose IL-2 (HDIL-2) was approved by the FDA for the treatment of metastatic renal cell carcinoma in 1992 and of metastatic melanoma in 1998 (Payne et al., 2014; Alva et al., 2016).